INCY - Incyte Corp Stock Price, Fair Value and News

$68.84+1.78 (+2.65%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

INCY Price Action

Last 7 days

0.4%

Last 30 days

-3.1%

Last 90 days

4.7%

Trailing 12 Months

11.6%

INCY RSI Chart

INCY Valuation

Market Cap

13.3B

Price/Earnings (Trailing)

408.29

Price/Sales (Trailing)

3.25

EV/EBITDA

33.02

Price/Free Cashflow

130.21

INCY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

INCY Fundamentals

INCY Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

23.81%

Rev. Growth (Qtr)

9.02%

INCY Earnings

Earnings (TTM)

32.5M

Earnings Growth (Yr)

-37.84%

Earnings Growth (Qtr)

123.94%

INCY Profitability

Operating Margin

92.80%

EBT Margin

6.72%

Return on Equity

1.02%

Return on Assets

0.65%

Free Cashflow Yield

0.77%

INCY Investor Care

Buy Backs (1Y)

14.04%

Diluted EPS (TTM)

0.14

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.8B	3.9B	4.1B	0
2023	3.5B	3.5B	3.6B	3.7B
2022	3.1B	3.3B	3.3B	3.4B
2021	2.7B	2.7B	2.9B	3.0B
2020	2.2B	2.4B	2.5B	2.7B
2019	2.0B	2.0B	2.1B	2.2B
2018	1.5B	1.7B	1.8B	1.9B
2017	1.2B	1.3B	1.4B	1.5B
2016	857.9M	941.2M	1.0B	1.1B
2015	581.0M	644.4M	633.8M	753.8M
2014	373.7M	371.6M	484.6M	511.5M
2013	332.0M	347.1M	371.7M	354.9M
2012	98.7M	168.4M	212.1M	297.1M
2011	184.6M	151.5M	151.4M	94.5M
2010	49.4M	89.6M	129.7M	169.9M
2009	0	0	0	9.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

CEO	Mr. Herve Hoppenot
WEBSITE	incyte.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	2324

Incyte Corp Frequently Asked Questions

What is the ticker symbol for Incyte Corp? What does INCY stand for in stocks?

INCY is the stock ticker symbol of Incyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Incyte Corp (INCY)?

As of Fri Dec 20 2024, market cap of Incyte Corp is 13.26 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers.

Is Incyte Corp a good stock to buy?

The fair value guage provides a quick view whether INCY is over valued or under valued. Whether Incyte Corp is cheap or expensive depends on the assumptions which impact Incyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INCY.

What is Incyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, INCY's PE ratio (Price to Earnings) is 408.29 and Price to Sales (PS) ratio is 3.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INCY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Incyte Corp's stock?

In the past 10 years, Incyte Corp has provided -0.001 (multiply by 100 for percentage) rate of return.